Basel / Hong Kong – March 2026
Quant Biomarkers (HK) Limited, a subsidiary of Quant Biomarkers AG, Switzerland, has received approval for admission to the IGNITE (Life & Health Technology) programme at the Hong Kong–Shenzhen Innovation and Technology Park (HSITP), including a milestone-based non-dilutive funding of approximately USD 750,000. The programme supports high-potential health technology companies and provides funding, infrastructure, and ecosystem access to accelerate development and regional expansion in Asia.
Quant Biomarkers is developing RenoRisk™, a novel biomarker panel for early injury detection, risk stratification, and treatment monitoring of chronic kidney disease, addressing a critical gap in preventive and precision medicine. As part of its Hong Kong strategy, Quant Biomarkers is establishing a collaboration with Chair Professor Tak Mao Daniel Chan at The University of Hong Kong, who is internationally recognised for his pioneering works in the treatment of kidney diseases, and also serving as Lead Author for the Lupus Nephritis Chapter in the KDIGO global nephrology guidelines. The collaboration will focus on advancing next-generation biomarker solutions in cardio-kidney-metabolic health. This collaboration is subject to contract finalisation and regulatory approvals.
Prof. Chan pointed out that “It is of critical importance that patients with kidney injury due to different etiologies are identified early for therapeutic intervention, before viable kidney tissue is replaced by irreparable scarring. And yet this is not feasible with currently available diagnostic biomarkers. The promising early data from the novel biomarker panel under investigation by Quant Biomarkers suggest that it could fill an important knowledge gap of great clinical significance.”
“Hong Kong offers a unique gateway to Asia’s healthcare ecosystem, and the HSITP platform enables us to accelerate both clinical validation and commercial deployment. Being selected for the HSITP IGNITE Programme is a strong validation of both our science and our international expansion strategy,” said Dr. Sanja Baumann-Tomovska, Co-Founder and CEO of Quant Biomarkers AG. “RenoRisk enables a shift from reactive to predictive care across cardio–renal–metabolic disease, creating actionable insights for clinicians, patients, and pharmaceutical partners.”
The company’s expansion into Hong Kong complements its existing collaborations with leading European institutions, including CHUV and the University of Zurich, and reflects its strategy to build a globally integrated precision diagnostics platform.
About Quant Biomarkers
Quant Biomarkers is a Swiss-based diagnostics company focused on next-generation biomarker solutions in cardio-kidney-metabolic diseases, enabling earlier detection, better risk prediction, treatment monitoring, and more personalised patient care.